Samiksha Jaiswal (Editor)

Resminostat

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Molar mass
  
349.4 g/mol

Pubchem
  
11609955

Density
  
1.282 g/cm³

ChemSpider ID
  
9784710

Resminostat wwwapexbtcommediadiyimagesstruct3dA4108png

Classification
  
Histone deacetylase inhibitor

Resminostat (4SC-201 or RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.
In 2011, the German drug maker 4SC was granted orphan drug designation for resminostat by the Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).

In 2016 the FDA granted [another?] IND for clinical tests in combination with sorafenib for HCC. 4SC say "In several phase I and phase II trials, resminostat has already demonstrated very good safety and tolerability, alongside promising indications of efficacy."

Mechanism

Resminostat restrains the phosphorylation of 4E-BP1 and p70S6k, indicating an disturbance with Akt signalling pathway.The treatment of resminostat leads to a drop of Bim and Bax protein level and Bcl-xL level.

As with other inhibitors such as pracinostat, the inhibition of HDACs by resminostat results in an accumulation of highly acetylated histones, followed by an abduction of chromatin remodeling, inhibition of tumor suppressor genes transcription and cell division, and finally tumor cell apoptosis.

References

Resminostat Wikipedia